Clinical study on the treatment of lumbar hyperosteogenywith Tenghuang-Jiangu tablet and osteopeptide injection
10.3760/cma.j.issn.1673-4246.2019.10.008
- VernacularTitle: 藤黄健骨片联合骨肽注射液治疗腰椎骨质增生症临床研究
- Author:
Qin LIU
1
;
Ning LI
2
;
Yanxia ZHU
3
Author Information
1. Cardiopulmonary Rehabilitation Center, Affiliated Taihe Hospital of Hubei University of Medicine, Shiyan 442000, China
2. Integrated TCM & Western Medicine Department, People's Hospital of Yunyang District, Shiyan 442500, China
3. Rehabilitation Department, Affiliated Taihe Hospital of Hubei University of Medicine, Shiyan 442000, China
- Publication Type:Clinical Trail
- Keywords:
Hyperostogeny;
Lumbar vertebrae;
Analgesics;
Osteopeptide injection;
Tenghuang-Jiangu tablet;
6-Ketoprostaglandin F1 alpha;
Thromboxane B2;
Integrated Chinese traditional and western medicine therapy
- From:
International Journal of Traditional Chinese Medicine
2019;41(10):1071-1074
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy of Tenghuang-Jiangu tablet combined with osteopeptide injection in the treatment of lumbar hyperosteogeny.
Methods:A total of 106 patients with lumbar hyperosteogeny were randomly divided into two groups, 53 in each group by digital table method. The control group was treated with osteopeptide injection, and the study group was treated with Tenghuang-Jiangu tablet on the basis of the control group. Both groups were treated for 45 days. The traditional Chinese medcine (TCM) symptoms were scored from pain, numbness, swelling, flexion and extension before and after treatment. The levels of thromboxane B2 (TXB2) and 6-ketone prostaglandin Flα ( 6-Keto-PGFlα ) in serum were detected by ELISA. Adverse reactions during treatment were recorded.
Results:The total effective rate was 86.8% (46/53) in the study group and 64.2% (34/53) in the control group. There were significant differences between the two groups (χ2=7.338, P=0.007). After treatment, the serum TXB2 (128.01 ± 23.68 pg/ml vs. 172.26 ± 19.33 pg/ml, t=10.539) level in the study group was significantly lower than control group (P<0.01); the serum 6-Keto-PGFlα (36.84 ± 4.96 pg/ml vs. 25.44 ± 4.21 pg/ml, t=12.757) level was significantly higher than control group (P<0.01). After treatment, the scores of pain, numbness, swelling, flexion and extension in the study group were significantly lower than those in the control group (t=10.061, 11.449, 14.921, 15.527, P<0.01). During the treatment period, the incidence of adverse reactions was 17.0% (9/53) in the control group and 22.6% (12/53) in the study group. There was no significant difference between the two groups (χ2=0.534, P=0.465).
Conclusions:The Tenghuang-Jiangu tablet combined with osteopeptide injection can improve the clinical symptoms of patients with lumbar hyperosteogeny, and regulate the serum levels of TXB2 and 6-Keto-PGFlα.
